The abstract is read at the publisher; the summary is JClub's.
A dendritic cell vaccine loaded with Bacteroides fragilis (DC-Bf) primes CD8+ T cells via MHC-I cross-presentation and improves tumor immunotherapy outcomes.
- Why it matters: Gut microbes can shape antitumor immunotherapy benefits, but translating specific commensals into clinical-grade vaccine strategies remains largely unexplored.
- What they did: DC-Bf was administered as a therapeutic cancer vaccine in multiple tumor-bearing models, assessing T cell cross-reactivity, CD8+ infiltration/activation, TCR diversity, and shifts in regulatory T cells and M2-type macrophages.
- The result: DC-Bf enhanced programmed cell death protein 1 inhibitor activity by inducing interleukin-12-driven, CD8+ T cell-dependent antitumor responses, supporting bacteria-loaded DCs as a way to augment immunotherapy efficacy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.